疫苗制造商应对季节性和大流行性流感病毒相关医疗需求的方法。
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.
作者信息
Baras Benoit, Bouveret Nancy, Devaster Jeanne-Marie, Fries Louis, Gillard Paul, Sänger Roland, Hanon Emmanuel
机构信息
GlaxoSmithKline Biologicals, Rixensart-Wavre, Belgium.
出版信息
Influenza Other Respir Viruses. 2008 Nov;2(6):251-60. doi: 10.1111/j.1750-2659.2008.00054.x.
Abstract
Vaccination is considered to be one of the most effective tools to decrease morbidity as well as mortality caused by influenza viruses. For the prevention of seasonal influenza, Fluarix and FluLaval have been marketed since 1987 and 1992, respectively. Both vaccines have consistently been shown to meet or exceed the regulatory criteria for immunogenicity against the three strains H1N1, H3N2 and B, have a good safety profile, and are recommended for vaccinating children and adults of all ages. For the prevention of pandemic influenza, GlaxoSmithKline (GSK) has obtained licensure of a pre-pandemic vaccine, Prepandrix. This split-virus H5N1 adjuvanted with AS03, a proprietary oil-in-water emulsion-based adjuvant system, has demonstrated broad immunity against drifted H5N1 strains and has been shown to be effective in preventing mortality and viral shedding in animal studies. The influenza vaccine portfolio of GSK addresses specific medical needs related to seasonal or pandemic influenza viruses, which remain an important public health threat worldwide.
摘要
接种疫苗被认为是降低流感病毒所致发病率和死亡率的最有效手段之一。为预防季节性流感，Fluarix和FluLaval分别于1987年和1992年上市。两种疫苗一直都显示出符合或超过针对H1N1、H3N2和B三种毒株免疫原性的监管标准，具有良好的安全性，并且推荐用于所有年龄段儿童和成人的接种。为预防大流行性流感，葛兰素史克公司（GSK）已获得一种大流行前疫苗Prepandrix的许可。这种与AS03（一种专有的水包油乳剂佐剂系统）佐剂结合的裂解病毒H5N1疫苗，已显示出对变异H5N1毒株具有广泛免疫力，并且在动物研究中已证明可有效预防死亡和病毒脱落。GSK的流感疫苗产品组合满足了与季节性或大流行性流感病毒相关的特定医疗需求，而这些病毒在全球范围内仍然是一项重大的公共卫生威胁。
相似文献
1
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.疫苗制造商应对季节性和大流行性流感病毒相关医疗需求的方法。
Influenza Other Respir Viruses. 2008 Nov;2(6):251-60. doi: 10.1111/j.1750-2659.2008.00054.x.
2
Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.大流行前甲型H5N1流感疫苗（裂解病毒、灭活、佐剂）[Prepandrix]：作为预防甲型H5N1流感病毒主动免疫制剂的应用综述
BioDrugs. 2008;22(5):279-92. doi: 10.2165/00063030-200822050-00001.
3
A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.一项关于在健康成年人中联合使用MF59®佐剂、大流行前A/H5N1疫苗和三价季节性流感疫苗的四价流感疫苗配方的II期研究。
Hum Vaccin Immunother. 2014;10(1):92-9. doi: 10.4161/hv.26495. Epub 2013 Sep 20.
4
Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.季节性流感与 MF59 佐剂 A/H5N1 疫苗联合、同时和序贯接种的免疫原性和安全性的 II 期随机对照试验：健康成年人。
J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.
5
Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.在小鼠中通过口服共同给予表达核蛋白的乳酸乳球菌并佐以霍乱毒素B亚基，对多种流感病毒产生广泛的保护性免疫。
Microb Cell Fact. 2015 Aug 5;14:111. doi: 10.1186/s12934-015-0287-4.
6
[Tetravaccine--new fundamental approach to prevention of influenza pandemic].[四联疫苗——预防流感大流行的新基本方法]
Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug(4):15-9.
7
MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.用于季节性和大流行性流感预防的MF59佐剂疫苗。
Influenza Other Respir Viruses. 2008 Nov;2(6):243-9. doi: 10.1111/j.1750-2659.2008.00059.x.
8
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.AS03 佐剂甲型 H5N1 流感疫苗加强免疫可改善异源加强免疫后的免疫应答动力学、幅度和持久性：一项双盲随机对照初级研究的开放性非随机扩展。
Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.
9
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.两剂全病毒和 AS03A 佐剂 2009 年甲型流感（H1N1）疫苗的免疫原性和安全性：一项随机、多中心、按年龄分层、头对头试验。
Lancet Infect Dis. 2011 Feb;11(2):91-101. doi: 10.1016/S1473-3099(10)70296-6. Epub 2010 Dec 16.
10
Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.MF59 佐剂四价流感病毒疫苗与非佐剂流感疫苗在儿童中的疗效、免疫原性和安全性评价：一项多中心、随机、对照、观察者盲、3 期临床试验。
Lancet Respir Med. 2018 May;6(5):345-356. doi: 10.1016/S2213-2600(18)30108-5. Epub 2018 Apr 6.
引用本文的文献
1
Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.保护受体结合域（RBD）二聚体以抵抗 SARS-CoV-2 及其变体。
J Virol. 2023 Nov 30;97(11):e0127923. doi: 10.1128/jvi.01279-23. Epub 2023 Oct 16.
2
Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response.基于角鲨烯的流感疫苗佐剂及其对血凝素特异性B细胞反应的影响。
Pathogens. 2021 Mar 17;10(3):355. doi: 10.3390/pathogens10030355.
3
A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.通过季节性流感建立的记忆 CD4 T 细胞动员克服禽流感疫苗免疫原性差的新型疫苗策略。
J Immunol. 2019 Sep 15;203(6):1502-1508. doi: 10.4049/jimmunol.1900819. Epub 2019 Aug 9.
4
Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.治疗性抗体的演变、流感病毒生物学、流感和流感免疫疗法。
Biomed Res Int. 2018 May 28;2018:9747549. doi: 10.1155/2018/9747549. eCollection 2018.
5
Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.聚γ-谷氨酸/壳聚糖纳米凝胶极大地增强了 H1N1 大流行性流感疫苗的效力和异源交叉反应性。
Sci Rep. 2017 Mar 21;7:44839. doi: 10.1038/srep44839.
6
A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.一种阳离子脂质体-DNA复合物佐剂（JVRS-100）可增强雪貂体内大流行前甲型流感病毒（H5N1）疫苗的免疫原性和交叉保护效力。
Virology. 2016 May;492:197-203. doi: 10.1016/j.virol.2016.02.024. Epub 2016 Mar 21.
7
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.一种佐剂化的四价登革病毒纯化灭活候选疫苗可在恒河猴中诱导针对登革热攻击的持久保护性抗体反应。
Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2.
8
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.使用佐剂CAF01配制的灭活脊髓灰质炎病毒诱导剂量节省。
PLoS One. 2014 Jun 23;9(6):e100879. doi: 10.1371/journal.pone.0100879. eCollection 2014.
9
Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.免疫衰老与老年人群流感疫苗接种的挑战。
Aging Dis. 2012 Feb;3(1):68-90. Epub 2011 Sep 30.
10
A rational, systematic approach for the development of vaccine formulations.制定疫苗制剂的合理、系统的方法。
AAPS J. 2011 Jun;13(2):191-200. doi: 10.1208/s12248-011-9261-1. Epub 2011 Feb 23.
本文引用的文献
1
Reference viruses for seasonal and pandemic influenza vaccine preparation.用于季节性流感疫苗和大流行性流感疫苗制备的参考病毒。
Influenza Other Respir Viruses. 2007 Jan;1(1):5-9. doi: 10.1111/j.1750-2659.2006.00003.x.
2
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.一种佐剂H5N1大流行候选疫苗在III期安全性试验中对成年人的安全性和反应原性情况
Vaccine. 2008 May 2;26(19):2378-88. doi: 10.1016/j.vaccine.2008.02.068. Epub 2008 Mar 27.
3
Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios.意大利大流行性流感的缓解措施：一个考虑不同情景的基于个体的模型。
PLoS One. 2008 Mar 12;3(3):e1790. doi: 10.1371/journal.pone.0001790.
4
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.一种佐剂化的1类rH5N1大流行性流感疫苗诱导的2类广泛交叉反应性免疫。
PLoS One. 2008 Feb 27;3(2):e1665. doi: 10.1371/journal.pone.0001665.
5
Update on avian influenza A (H5N1) virus infection in humans.人感染甲型H5N1禽流感病毒的最新情况。
N Engl J Med. 2008 Jan 17;358(3):261-73. doi: 10.1056/NEJMra0707279.
6
Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.用一种佐剂大流行性流感疫苗对雪貂进行致死性H5N1攻击的交叉保护。
PLoS One. 2008 Jan 2;3(1):e1401. doi: 10.1371/journal.pone.0001401.
7
Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years.三价流感裂解疫苗在6至9岁和10至13岁未接种过疫苗儿童中的免疫原性和反应原性。
Vaccine. 2007 Dec 21;26(1):32-40. doi: 10.1016/j.vaccine.2007.10.049. Epub 2007 Nov 9.
8
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.葛兰素史克疫苗中的佐剂系统：概念、成就与展望。
Expert Rev Vaccines. 2007 Oct;6(5):723-39. doi: 10.1586/14760584.6.5.723.
9
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.一种佐剂化重组H5N1大流行性流感原型疫苗的抗原节省和交叉反应性免疫：一项随机对照试验。
Lancet. 2007 Aug 18;370(9587):580-9. doi: 10.1016/S0140-6736(07)61297-5.
10
Pre- or post-pandemic influenza vaccine?大流行前还是大流行后的流感疫苗？
Vaccine. 2007 Jun 28;25(27):4983-4. doi: 10.1016/j.vaccine.2007.05.033. Epub 2007 May 29.
Zotero 插件